Overview Dividends

(VCYT) Veracyte - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US92337F1075

Thyroid, Prostate, Bladder, Breast, Lung

Biotechnology
Market Cap in USD: 3,351m
IPO / Inception: 2013-10-30
Return 12m vs S&P 500: -10.4%

EPS (Earnings per Share)

EPS (Earnings per Share) of VCYT over the last years for every Quarter: "2020-12": -0.14, "2021-03": -0.11, "2021-06": -0.13, "2021-09": -0.2, "2021-12": -0.15, "2022-03": -0.2, "2022-06": -0.13, "2022-09": -0.12, "2022-12": -0.05, "2023-03": -0.11, "2023-06": -0.12, "2023-09": -0.41, "2023-12": -0.39, "2024-03": -0.02, "2024-06": 0.07, "2024-09": 0.19, "2024-12": 0.36, "2025-03": 0.31, "2025-06": 0.44, "2025-09": 0.51, "2025-12": 0,
EPS CAGR: 18.42%
EPS Trend: 69.9%
Last SUE: -1.75
Qual. Beats: 0

Revenue

Revenue of VCYT over the last years for every Quarter: 2020-12: 34.536, 2021-03: 36.703, 2021-06: 55.105, 2021-09: 60.37, 2021-12: 67.336, 2022-03: 67.783, 2022-06: 72.864, 2022-09: 75.592, 2022-12: 80.297, 2023-03: 82.422, 2023-06: 90.322, 2023-09: 90.108, 2023-12: 98.199, 2024-03: 96.844, 2024-06: 114.428, 2024-09: 115.86, 2024-12: 118.632, 2025-03: 114.473, 2025-06: 130.164, 2025-09: 131.872, 2025-12: null,
Rev. CAGR: 19.63%
Rev. Trend: 98.9%
Last SUE: 1.85
Qual. Beats: 3

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 50.5%
Value at Risk 5%th 75.0%
Relative Tail Risk -9.65%
Reward TTM
Sharpe Ratio 0.27
Alpha -13.29
CAGR/Max DD 0.43
Character TTM
Hurst Exponent 0.818
Beta 1.224
Beta Downside 0.828
Drawdowns 3y
Max DD 50.09%
Mean DD 19.01%
Median DD 17.28%

Description: VCYT Veracyte November 11, 2025

Veracyte, Inc. (NASDAQ: VCYT) is a molecular diagnostics firm that commercializes genomic classifiers for several cancer types, including Afirma for thyroid nodules, Decipher for prostate and bladder cancers, Prosigna for breast cancer, and Percepta for lung cancer, while also developing the nCounter analysis platform. The company, incorporated in 2006 and headquartered in South San Francisco, rebranded from Calderome in 2008.

As of FY 2023, Veracyte reported $281 million in revenue-a 22 % year-over-year increase driven primarily by expanding Decipher adoption in the United States and new international contracts for Afirma. The firm holds roughly 30 % market share in the thyroid molecular testing space and benefits from a broader industry shift toward reimbursable, precision-medicine diagnostics, which the U.S. Centers for Medicare & Medicaid Services (CMS) has begun to recognize for several of its assays. Additionally, a strategic partnership with Roche to co-market Afirma in Europe is expected to accelerate international revenue growth.

For a deeper dive into Veracyte’s valuation dynamics and how they compare with peers, you might explore the analytical tools on ValueRay to assess the company’s risk-adjusted upside.

Piotroski VR‑10 (Strict, 0-10) 6.0

Net Income (30.3m TTM) > 0 and > 6% of Revenue (6% = 29.7m TTM)
FCFTA 0.07 (>2.0%) and ΔFCFTA 2.75pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 76.15% (prev 67.37%; Δ 8.79pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.08 (>3.0%) and CFO 108.2m > Net Income 30.3m (YES >=105%, WARN >=100%)
Net Debt (-275.1m) to EBITDA (47.1m) ratio: -5.84 <= 3.0 (WARN <= 3.5)
Current Ratio 6.23 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (79.7m) change vs 12m ago 1.56% (target <= -2.0% for YES)
Gross Margin 68.14% (prev 67.76%; Δ 0.38pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 37.47% (prev 33.36%; Δ 4.11pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 12.4k (EBITDA TTM 47.1m / Interest Expense TTM 2000 ) >= 6 (WARN >= 3)

Altman Z'' -3.13

(A) 0.28 = (Total Current Assets 449.2m - Total Current Liabilities 72.2m) / Total Assets 1.37b
(B) -0.31 = Retained Earnings (Balance) -418.8m / Total Assets 1.37b
(C) 0.02 = EBIT TTM 24.7m / Avg Total Assets 1.32b
(D) -3.88 = Book Value of Equity -426.9m / Total Liabilities 110.1m
Total Rating: -3.13 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 63.28

1. Piotroski 6.0pt
2. FCF Yield 3.25%
3. FCF Margin 19.83%
4. Debt/Equity 0.03
5. Debt/Ebitda -5.84
6. ROIC - WACC (= -8.34)%
7. RoE 2.50%
8. Rev. Trend 98.87%
9. EPS Trend 69.95%

What is the price of VCYT shares?

As of January 08, 2026, the stock is trading at USD 45.11 with a total of 669,576 shares traded.
Over the past week, the price has changed by +7.15%, over one month by +1.69%, over three months by +30.34% and over the past year by +6.17%.

Is VCYT a buy, sell or hold?

Veracyte has received a consensus analysts rating of 4.27. Therefore, it is recommended to buy VCYT.
  • Strong Buy: 7
  • Buy: 2
  • Hold: 1
  • Sell: 0
  • Strong Sell: 1

What are the forecasts/targets for the VCYT price?

Issuer Target Up/Down from current
Wallstreet Target Price 47.5 5.3%
Analysts Target Price 47.5 5.3%
ValueRay Target Price 44.2 -2%

VCYT Fundamental Data Overview January 05, 2026

Market Cap USD = 3.35b (3.35b USD * 1.0 USD.USD)
P/E Trailing = 111.5526
P/E Forward = 28.3286
P/S = 6.7676
P/B = 2.6644
Beta = 1.83
Revenue TTM = 495.1m USD
EBIT TTM = 24.7m USD
EBITDA TTM = 47.1m USD
Long Term Debt = 40.5m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 4.28m USD (from shortTermDebt, last quarter)
Debt = 40.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -275.1m USD (from netDebt column, last quarter)
Enterprise Value = 3.02b USD (3.35b + Debt 40.5m - CCE 366.4m)
Interest Coverage Ratio = 12.4k (Ebit TTM 24.7m / Interest Expense TTM 2000 )
FCF Yield = 3.25% (FCF TTM 98.2m / Enterprise Value 3.02b)
FCF Margin = 19.83% (FCF TTM 98.2m / Revenue TTM 495.1m)
Net Margin = 6.12% (Net Income TTM 30.3m / Revenue TTM 495.1m)
Gross Margin = 68.14% ((Revenue TTM 495.1m - Cost of Revenue TTM 157.8m) / Revenue TTM)
Gross Margin QoQ = 67.76% (prev 68.97%)
Tobins Q-Ratio = 2.21 (Enterprise Value 3.02b / Total Assets 1.37b)
Interest Expense / Debt = 0.00% (Interest Expense 2000 / Debt 40.5m)
Taxrate = -1.31% (negative due to tax credits) (-248.0k / 18.9m)
NOPAT = 25.1m (EBIT 24.7m * (1 - -1.31%)) [negative tax rate / tax credits]
Current Ratio = 6.23 (Total Current Assets 449.2m / Total Current Liabilities 72.2m)
Debt / Equity = 0.03 (Debt 40.5m / totalStockholderEquity, last quarter 1.26b)
Debt / EBITDA = -5.84 (Net Debt -275.1m / EBITDA 47.1m)
Debt / FCF = -2.80 (Net Debt -275.1m / FCF TTM 98.2m)
Total Stockholder Equity = 1.21b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.22% (Net Income 30.3m / Total Assets 1.37b)
RoE = 2.50% (Net Income TTM 30.3m / Total Stockholder Equity 1.21b)
RoCE = 1.98% (EBIT 24.7m / Capital Employed (Equity 1.21b + L.T.Debt 40.5m))
RoIC = 2.07% (NOPAT 25.1m / Invested Capital 1.21b)
WACC = 10.40% (E(3.35b)/V(3.39b) * Re(10.53%) + D(40.5m)/V(3.39b) * Rd(0.00%) * (1-Tc(-0.01)))
Discount Rate = 10.53% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 4.41%
[DCF Debug] Terminal Value 73.79% ; FCFE base≈81.5m ; Y1≈100.6m ; Y5≈171.6m
Fair Price DCF = 24.39 (DCF Value 1.93b / Shares Outstanding 79.0m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 69.95 | EPS CAGR: 18.42% | SUE: -1.75 | # QB: 0
Revenue Correlation: 98.87 | Revenue CAGR: 19.63% | SUE: 1.85 | # QB: 3
EPS next Quarter (2026-03-31): EPS=0.34 | Chg30d=+0.037 | Revisions Net=+2 | Analysts=11
EPS next Year (2026-12-31): EPS=1.60 | Chg30d=+0.001 | Revisions Net=+6 | Growth EPS=-2.5% | Growth Revenue=+11.3%

Additional Sources for VCYT Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle